Irofulven API Manufacturers

General Description:

Irofulven, identified by CAS number 158440-71-2, is a notable compound with significant therapeutic applications. A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track” status by the U.S. Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers. MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc, an emerging oncology-focused pharmaceutical company based in Minneapolis. Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.

Indications:

This drug is primarily indicated for: Investigated for use/treatment in brain cancer, breast cancer, endometrial cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, pediatric indications, prostate cancer, and sarcoma. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Mechanism of Action:

Irofulven functions by: MGI-114(Irofulven) has unique mechanism of action as an anti-tumor agent is due to its ability to be rapidly absorbed by tumor cells. Once inside the cells, the compound binds to DNA and protein targets. This binding interferes with DNA replication and cell division of tumor cells, leading to tumor-specific apoptotic cell death, or “cell suicide.” During this process, tumor cells tend to automatically shut themselves down when they sense their function is compromised. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Classification:

Irofulven belongs to the class of organic compounds known as cyclohexenones. These are compounds containing a cylohexenone moiety, which is a six-membered aliphatic ring that carries a ketone and has one endocyclic double bond, classified under the direct parent group Cyclohexenones. This compound is a part of the Organic compounds, falling under the Organic oxygen compounds superclass, and categorized within the Organooxygen compounds class, specifically within the Carbonyl compounds subclass.

Categories:

Irofulven is categorized under the following therapeutic classes: Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Noxae, Radiation-Sensitizing Agents, Terpenes, Toxic Actions. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.